Late-breaker presentations at the American Society of Hematology (ASH) annual meeting Dec. 1-4 in San Diego for Darzalex (daratumumab) and Imbruvica (ibrutinib) could position the drugs as new standards of care in newly diagnosed multiple myeloma and untreated chronic lymphocytic leukemia (CLL).
Editor’s note:
Please see "
Outside of blood cancers, new treatments have the potential to reduce transfusion dependence in beta-thalassemia. In particular, Phase III results for luspatercept from Acceleron Pharma Inc
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?